Wave Neuroscience

The escalating prevalence of Post-Traumatic Stress Disorder (PTSD) in both military and civilian populations, including first responders, has become a critical public health issue. Currently, there are no FDA approved devices that treat this irreversibly debilitating condition. There is an urgent need for innovative, non-pharmacologic, safe and effective treatments for PTSD to address this underserved patient population. The Breakthrough Device Designation is awarded to treatments that have demonstrated the potential to provide more effective treatment for life-threatening or irreversibly debilitating conditions. While Breakthrough Designation does not indicate FDA clearance, this designation will help Wave Neuroscience to address this critical healthcare need by accelerating the development, assessment, and ultimately the review of Wave's FDA submissions for the use of the MeRT system for more effective treatment of PTSD patients. #PTSD #MentalHealth #waveneuro #brainhealth

We are excited to share that Pulse 2.0 recently interviewed our fearless leader, Wave Neuroscience CEO Fred Walke. Fred revealed what motivates him and why Wave Neuroscience is passionately driven to provide neurotechnology solutions that impact the mental health journey one patient at a time. Read the article at pulse2.com. Pulse 2.0

1 in 5 U.S. adults experiences mental illness each year - help is available. Today is World Mental Health Day and we encourage everyone to take a moment to check in with themselves and their loved ones. Early detection can be life-changing. #DepressionScreeningDay #MentalHealthAwareness #CheckInWithYourself"

Breaking the stigma starts with understanding. During Mental Illness Awareness Week, we recognize the importance of education, empathy, and support for those facing mental health challenges. Let’s come together to promote a world where mental health is a priority for everyone. #MentalIllnessAwarenessWeek #BreakTheStigma #MentalHealthMatters"

Read about MeRT® in this peer reviewed article recently published in Frontiers in Psychiatry. To our knowledge, this is the first chart review of an optimization program using α rTMS deployed in a population of active-duty special forces personnel which underscores our commitment to advancing the field of neuroscience and supporting mental health through cutting-edge research and innovation. We are dedicated to improving brain health and focused on developing impactful solutions for the broader mental health community. MeRT is currently under evaluation for an FDA clearance specific to PTSD. Visit the media page on our website to read more. waveneuro.com/media #MeRT #PTSD #FrontiersinPsychiatry

Join our webinar on MeRT™ Technology!  Registration link: https://lnkd.in/gRhD6YaS Join Dr. Erik Won, Chief Medical Officer at Wave Neuroscience, for an exclusive webinar where he'll dive deep into MeRT™ technology. Don't miss this chance to learn about how MeRT™ technology is revolutionizing brain health! 🧠✨ #WaveNeuroscience #MeRT #BrainHealth

Wave Neuroscience is thrilled to announce our participation in the 2024 Annual Neuromodulation Meeting in New York! 🗽✨ Our team is eager to share insights, connect with industry leaders, and showcase our technology. Come visit us at our booth to discover the latest innovations pioneered by Wave Neuroscience. #NYCN2024 #Neuromodulation2024 #WaveNeuroscience #NYC #Innovation #MentalHealth #BrainOptimization #PTSDTreatment

Listen to Dr. Erik Won, Wave Neuroscience Chief Medical Officer, discuss with Dr. Gabrielle Lyon technological advances in brain injury and PTSD, the role of EEG and TMS in treating brain injuries and future direction and ongoing clinical trials for Wave Neuroscience. MeRT™ is currently under evaluation for an FDA clearance specific to PTSD. Check out the episode here: https://lnkd.in/gtypBxkH

Join us in raising awareness for PTSD and applauding all efforts to increase advocacy, treatment and advance scientific understanding. According to the World Health Organization (WHO), around 3.9% of the world's population has experienced post-traumatic stress disorder (PTSD) at some point in their lives. In the United States, about 5% of adults, or 13 million people, have PTSD in any given year.

Wave Neuroscience is excited to attend the Clinical TMS Society Annual Meeting in London from June 13-15, 2024! Join us at Booth #103 to discover how Wave Neuroscience is leading new frontiers in PTSD therapy and explore how our proprietary software personalizes TMS. #clinicalTMS #WaveNeuroscience #EEGguidedTMS #CTMS